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Abstract 
Frontotemporal lobar degeneration (FTLD) is the second most common cause for 
dementia before 65 years of age. FTLD comprises variants with a very diverging spectrum, 
regarding the clinical presentation, genetic features, and neuropathology. 
In the last decades remarkable progresses have been achieved in terms of genetic 
causes and their relation with neuropathology. Given the complexity of this disease, several 
aetiologies have been proposed. One of the theories includes variations in mitochondrial DNA 
(mtDNA) that affect the energy production in mitochondrial respiratory chain and 
consequently affect the tissue with higher energy demands, the central nervous system. 
The aim of our study is to identify variations of MT-CYB gene in 70 DNA samples of 
patients with probable diagnosis of FTLD.  
Total DNA of the samples was extracted from peripheral blood and MT-CYB gene was 
analysed and the sequence variations found were submitted to an in silico analysis. A total of 
37 different sequence variations were identified in 44 patients (63%): 22 are synonymous, 2 
are novel variations (m.15073C>T; m.15127C>T) that have not been reported to date in 
MITOMAP database and 15 are non-synonymous. 
The results of the in silico analysis suggested that 3 variations may be pathogenic: 
m.14927A>C affects protein function according to SIFT and the amino acid is conserved in 
all mammals; m.15164T>C is predicted to be deleterious by Provean, it is an alteration in a 
critical position and is totally conserved in all species studied, and m.15465T>C affects 
protein function according to Poly-Phen and SIFT and is highly conserved in mammals. 
Further investigation is important to clarify a possible relationship between mtDNA 
variations and pathophysiology of FTLD. However, our study represents a significant 
improvement in the complex field of dementia such like FTLD. 
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Abbreviations 
AD Alzheimer’s Disease 
aFTLD-U Atypical frontotemporal lobar degeneration 
with ubiquitinated inclusions 
AGD Argyrophilic grain disease 
APOE Apolipoprotein E 
avPPA Agrammatical variant of PPA 
BIBD Basophilic inclusion body disease 
bvFTD Behavioural variant frontotemporal dementia 
C9ORF72 Chromosome 9 open reading frame 21 
CBS Cortico basal syndrome 
CDR Clinical Dementia Rating 
CHMP2B Chromatin-modifying protein 2B 
CHMP2B Charged multivescicular body protein 2B 
CST 3B Cystatin C gene 
DLDH Dementia lacking distinctive histopathology 
FTD Frontotemporal dementia 
FTD-3 Frontotemporal dementia linked to 
chromosome 3 
FTD–MND FTD with motor neuron disease 
FTLD Frontotemporal lobar degeneration 
FTLD-U FTLD-Ubiquitin 
FTLD-UPS FTLD ubiquitin proteasome system 
FUS Fused in sarcoma 
LHON Leber's hereditary optic neuropathy 
LNVC Left ventricular noncompaction 
MAPT Microtubule-associated protein tau 
MDD Major depressive disorder 
MMSE Mini-Mental State Examination 
MRC Mitochondrial respiratory chain 
MSTD Multiple system tauopathy with dementia 
MT-CYB Gene encoding cytochrome b 
mtDNA Mitochondrial DNA 
NFT-dementia Neurofibrillary tangle predominant dementia 
Ni No inclusions 
NIFID Neuronal intermediate filament inclusion 
disease 
PGRN or GRN Progranulin 
PiD Pick’s disease 
PPA Primary progressive aphasia 
PSP Progressive supranuclear palsy 
RFLP Restriction fragment length polymorphism 
ROS Reactive oxygen species 
svPPA Semantic variant of primary progressive 
aphasia 
TAR Transactive response 
TARDBP TAR DNA-binding protein 43 
TARDBP Transactive response DNA binding protein 
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TDP-43 TAR DNA-binding protein 43 kDa 
VCP Valosin-containing protein 
WMT-GGI White matter tauopathy with globular glial 
inclusions 
9p Genetic locus on chromosome 9p linked to 
familial amyotrophic lateral sclerosis and 
frontotemporal dementia 
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Introduction 
In the last years, the interest in the study of diseases that are prevalent at older ages has 
increased, particularly because of ageing of the population worldwide. The prevalence of 
neurodegenerative dementias have also increased, including the frontotemporal lobar 
degeneration (FTLD), which is the most common cause of the non-Alzheimer type dementia 
worldwide (Borroni & Padovani, 2013). The FTLD accounts for about 9% of all cases of 
dementia (Salmon & Stuss, 2013) and is particularly prevalent in patients under than 65 years 
dementia (Neary et al., 2005, Seelaar et al., 2011, Sieben et al., 2012), being the second most 
common early-onset dementia (Seelaar et al., 2011). 
The exact prevalence of FTLD remains uncertain, however the incidence appears to be 
equal in both genders (Neary et al., 2005, Seelaar et al., 2011). It is a clinically and 
pathologically heterogeneous spectrum of syndromes, characterized by a progressive decline 
in behavior or language associated difficulties with selective degeneration of the frontal and 
temporal cortex regions, with relative preservation of posterior regions (Seelaar et al., 2011, 
Shinagawa, 2013). 
Nomenclature of the FTLD spectrum phenotypes is complex as new pathological and 
genetic correlations have been recently discovered (Hales & Hu, 2013, Sieben et al., 2012). 
Accordingly, current redefined clinical criteria recognize several different phenotypes, 
namely: behavioural variant frontotemporal dementia (bvFTD), the semantic variant of 
primary progressive aphasia (svPPA), the agrammatical variant of PPA (avPPA), FTD with 
motor neuron disease (FTD–MND), cortico basal syndrome (CBS) and progressive 
supranuclear palsy (PSP) (Borroni & Padovani, 2013, Shinagawa, 2013). The bvFTD subtype 
has the highest prevalence amongst the FTLD clinical syndromes, accounting for 
approximately 70% of all cases (Pan & Chen, 2013). The bvFTD, svPPA and avPPA 
phenotypes all share an insidious onset and inexorably progressive decline. Emotional 
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blunting, loss of empathy, apathy, selfishness and neglect of personal hygiene are typical of 
bvFTD, but that may be seen in all subtypes (Seelaar et al., 2011). 
In contrast to Alzheimer’s Disease (AD) patients, subjects affected with FTLD usually 
perform relatively well in visuospatial ability and memory tasks (Grazina et al., 2004, 
Schlachetzki, 2011, Wang et al., 2013). 
The clinical heterogeneity in familiar and sporadic forms of FTLD is remarkable, with 
patients demonstrating variable mixtures of disinhibition, dementia, PSP, CBD, and MND 
(Pan & Chen, 2013, Sleegers et al., 2010). 
The autosomal dominant transmission of the disease suggested a genetic cause 
(Galimberti & Scarpini, 2012) and approximately 40% of patients with FTLD have a positive 
family history (Pan & Chen, 2013). However, only 10%–30% of family pedigrees show an 
autosomal dominant inheritance pattern (Riedl et al., 2014, Sieben et al., 2012). 
Mutations in the genes of microtubule-associated protein tau (MAPT), accounting for 
50% of familial cases of FTLD (Riedl et al., 2014), and mutations in progranulin (PGRN or 
GRN), and Chromosome 9 open reading frame 21 (C9ORF72) have been shown as the major 
causes of FTLD (Sieben et al., 2012, Wang et al., 2013). Minority of cases are caused by 
mutations in 4 other genes (Table 1): valosin-containing protein (VCP), TAR DNA-binding 
protein 43 (TARDBP), chromatin-modifying protein 2B (CHMP2B), and fused in sarcoma 
(FUS) (Mackenzie et al., 2010, Pan & Chen, 2013, Wang et al., 2013). However, given the 
incomplete penetrance of such mutations, a large number of cases are apparently sporadic, 
making more difficult to suspect the presence of a causal mutation (Galimberti & Scarpini, 
2012). 
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Table 1: Genetic factors in inherited FTLD (Adapted from Sieben et al., 2012). 
Gene symbol Chromosomal 
location 
Gene name Mutation 
frequency 
C9orf72 9p21.2 Chromosome 9 open reading frame 21 14 – 48 % 
GRN 17q21.32 Progranulin 3 – 26 % 
MAPT 17q21.1 Microtubule-associated protein tau 0 – 50 % 
CHMP2B 3p11.2 Charged multivesicular body protein 2B <1% 
VCP 9p13.3 Valosin-containing protein <1% 
 
 
In fact, the majority of the FTLD cases are sporadic without a definite known cause 
(Kalkonde et al., 2012). It is possible that environmental or inflammatory autoimmune factors 
contribute to the risk of develop this dementia (Kalkonde et al., 2012, Mcmillan et al., 2013). 
In addition, the first candidate-gene studied in FTLD was the well-known risk factor for late 
onset sporadic AD, APOE (Galimberti & Scarpini, 2012) and an increase in the risk for FTLD 
has been reported with APOE genotypes 2 and 4 contributing to sporadic variant and  
(CST3B) gene in association with PGRN (Kalkonde et al., 2012). 
Considering the variability in clinical features and molecular genetics, it is not 
surprising that the neuropathology associated with FTLD is also heterogeneous (Riedl et al., 
2014). Thus, immunohistochemistry analysis allows subcategorization of these spectrum 
disorders into specific proteinopathies based on the major component of the inclusions, such 
as FTLD-tau: the cells contain inclusions of hyperphosphorylated tau protein (Mackenzie et 
al., 2010), FTLD-Ubiquitin (FTLD-U). Over 50% of the FTLD patients present tau-negative 
ubiquitin staining inclusions. This FTLD-U inclusions were found to be composed of 
transactive response (TAR) DNA-binding protein 43 kDa (TDP-43), referred as FTLD-TDP, 
or inclusions of fused in-sarcoma protein (FUS) and TDP-43-negative, referred to as FTLD-
FUS (Pan & Chen, 2013). However, in a small number of FTLD-U patients, the inclusion 
protein remains unclear (Mackenzie et al., 2010); this group is referred as FTLD ubiquitin 
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proteasome system (FTLD-UPS). There is other type of dementia lacking distinctive 
histopathology (DLDH) and there are also other rare types, such like dementia with basophilic 
inclusion body or neuronal intermediate filament inclusion disease (Pan & Chen, 2013). 
Moreover, given that the most cases of FTLD have abnormal intracellular 
accumulation of some disease-specific protein, it has become popular to classify FTLD into 
broad categories, based on the molecular defect thought to be most abundant, which allows 
pathological diagnosis (Riedl et al., 2014). 
One of the most intriguing issues in the FTLD field is the poor correspondence 
between neuropathological features and clinical phenotypes. So far, neuropathological 
characteristics are only predictable in known genetic defects (Borroni & Padovani, 2013). In 
fact, these genetic causes of FTLD have 100% correspondence between mutations detectable 
during life and the FTLD pathological substrate (Table 2), only visible at autopsy (Hales & 
Hu, 2013). In addition, genetic screening for patients with known family history of FTLD or 
early onset behavior/language disorders can inform the exact FTLD pathological substrate for 
both diagnosis and enrolment into therapeutic trials (Borroni & Padovani, 2013, Hales & Hu, 
2013). 
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Table 2: Nomenclature for Frontotemporal Lobar Degeneration  
based on genetics (Adapted from Mackenzie et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pathophysiological mechanisms underlying the remaining 60% to 80% sporadic 
cases of FTLD are unclear (Wang et al., 2013). One possible theory is that mutations located 
in mitochondrial DNA (mtDNA) have a key part in neurodegeneration (Grazina et al., 2004, 
Swerdlow & Khan, 2004). 
Primary respiratory chain diseases can be thought as the resulting of mutations in 
mtDNA or nuclear genes encoding mitochondrial respiratory chain (MRC) subunits. Since 
mtDNA encodes 13 proteins of the MRC, the mutations of mtDNA usually induce defects of 
MRC (Schapira, 2012). The mitochondrial theory of ageing proposes that mutations in 
mtDNA occur throughout life, due to either oxidative damage, with the increase of reactive 
oxygen species (ROS) production, or to errors of the mtDNA polymerase, and these 
mutations clonally expand to cause cellular dysfunction (Greaves et al., 2012). Additionally, 
Major molecular 
class 
Recognized 
subtype 
Associated gene 
FTLD-tau PiD 
CBD 
PSP 
AGD 
MSTD 
NFT-dementia 
WMT-GGI 
Unclassifiable 
MAPT 
FTLD-TDP Types 1-4 
Unclassifiable 
GRN 
VCP 
9p 
TARDBP 
FTLD-UPS FTD-3 CHMP2B 
FTLD-FUS aFTLD-U 
NIFID 
BIBD 
FUS 
FTLD-ni Not known Not known 
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the clinical features usually affect particularly tissues in which there is a high metabolic 
demand, such as the central nervous system, skeletal muscle or heart (Greaves et al., 2012, 
Leonard & Schapira, 2000). 
Mitochondrial dysfunction has been identified in several neurodegenerative disorders 
like AD (Dimauro & Schon, 2008, Grazina et al., 2006, Grazina et al., 2005), Huntington’s 
disease (Dimauro & Schon, 2008, Lee et al., 2009), Parkinson's disease (Dimauro & Schon, 
2008, Federico et al., 2012) and amyotrophic lateral sclerosis (Dimauro & Schon, 2008, Lee 
et al., 2009), among others. 
Evidences indicate that mitochondrial function is affected in AD, including reduction 
in brain energy metabolism, metabolic enzyme and MRC proteins deficiency (Dimauro & 
Schon, 2008, Grazina et al., 2006). 
As mitochondria play a role in the pathogenesis of several neurodegenerative diseases, 
it would be reasonable to invoke similar mechanisms for FTLD. 
Furthermore, the neuropathological and clinical overlapping of AD and FTLD occur in 
some patients, such as focal TDP-43 lesions in AD and, conversely, mild AD pathology in 
FTLD-TDP add further complexity (Hales & Hu, 2013). Thus, mtDNA sequence variations 
may be an important factor for both diseases (Grazina et al., 2004). 
In mitochondrial cytopathies, isolated or combined deficiencies in Complex III of 
MRC are rare, but mutations in mtDNA gene encoding cytochrome b (MT-CYB) account for 
the most described to date (Schapira, 2012). 
According to these references, the aim of this study is sequencing the MT-CYB gene in 
patients diagnosed with FTLD in the scope of a project funded by FCT (PI Professor Manuela 
Grazina). 
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Patients and Methods 
The DNA samples included in the study belong to 70 patients (31 males and 39 
females; mean age: 63 years; range: 38 to 82 years of age) with probable diagnosis of FTLD 
according to the Diagnostic and Statistical Manual of Mental Disorders – fourth edition 
(DSM-IV-TR) criteria (APA, 1994) and FTLD was classified following the Lund and 
Manchester clinical criteria (Groups, 1994) revised by the Work Group on Frontotemporal 
Dementia and Pick’s Disease (Mcknann et al., 2001), and more recently according to the 
International Behavioural Variant Frontotemporal Dementia Criteria Consortium for bvFTD 
(Rascovsky et al., 2011). A control population was included, for setting reference values in 
our sample, composed by individuals without subjective cognitive complaints, whom 
performed on the normal range for education in the Mini-Mental State Examination (MMSE) 
and were independent in their instrumental daily life activities. This study had the approval of 
the Ethics Committee, following the Tenets of the Helsinki Declaration, and informed consent 
was obtained from all participants. Global cognitive impairment was quantified using the 
MMSE (Folstein et al., 1975). 
The patients were followed at Dementia Consultation of the Neurological Unit of the 
“Centro Hospitalar e Universitário de Coimbra”. The mean age of onset was 58 years, ranging 
from 34 to 79 years. Taking into account the clinical variants, 60 patients (85.7%) presented 
bvFTD, while 4 (5.7%) had bvFTD with CBS, other 4 (5.7%) presented avPPA and 2 (2.8%) 
showed svPPA. A table with patients’ characterization can be found in appendix 1. 
The arbitrary cut off at 65 years was used to differentiate the early onset (below) from 
late onset (equal or above) cases. 
Total cellular DNA (nuclear plus mitochondrial) was extracted from peripheral blood 
leukocytes, isolated after erythrocytes lysis using a standard phenol-chloroform method. After 
amplification of mtDNA fragments with PCR, the automated sequencing analysis was 
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performed using 3130 ABI Prism sequencing system with BigDye® Terminator Ready 
Reaction Mix 3.1 (Applied Biosystems) and specific primers (Landsverk et al., 2012) that 
flanked the gene sequence in order to study MT-CYB. The sequences obtained were compared 
with the human mtDNA revised Cambridge reference sequence (Andrews et al., 1999), 
obtained from GenBank. The Sequencing Analysis® v.5.4 and SeqScape® v.2.5 softwares 
(Applied Biosystems) allowed the identification of sequence variations. All variations were 
classified using the MITOMAP database (http://www.mitomap.org) and the frequency was 
obtained in the Human Mitochondrial Genome Database and from (Pereira et al., 2009), in 
order to estimate its frequency in general population. 
The next step performed was an in silico analysis of the non-synonymous variations 
using different bioinformatic tools: Polyphen v. 2.2.2, which is an automatic tool used to 
predict the possible impact of an amino acid substitution on the structure and function of the 
corresponding protein, using information of the sequence, phylogenetic and structural 
characteristics of the substituted sequence (Adzhubei et al., 2010); SIFT, that gives the same 
type of prediction based on aligned sequences provided by the user, accounting on 
conservation of the alignment sequences in different species (Kumar et al., 2009); Mutation 
Assessor v. 2 that predicts the functional impact of amino acid substitution in protein, based 
on evolutionary conservation of the affected amino acid in protein homologous (Reva et al., 
2011); Provean is similar to the former but calculates the mutation score by the average of 
each sub-family average score (Choi et al., 2012). 
When alignment of sequences was necessary, the sequences of 14 different species, 
from UniProt® database, were selected (Homo sapiens, Gorilla, Pan troglodytes, Pongo 
pygmaeus, Pan-paniscus, Rattus norvegicus, Mus Musculus, Bos Taurus, Gallus gallus, 
Xenopus laevis, Danio rerio, Strongylocentrotus purpuratus, Drosophilla melanogaster, 
Caenorhabditis elegans). Evolutionary conservation was performed to all sequence variations 
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using ClustalW2®, which is a multiple sequence alignment program that uses seeded guide 
trees to generate alignments, enabling to visualize the alignment of the selected sequences 
(Larkin et al., 2007). 
The novel sequence variations found were confirmed by a second method, such as 
Restriction fragment length polymorphism (RFLP) analysis using specific endonucleases: 
BseMII for m.15073C>T and Alu I for m.15127C>T (Thermo Scientific) following the 
manufactures’ instructions. 
A statistical analysis was performed to correlate some variables with the genetic 
variations founded in MT-CYB in different patients. The t-test or Mann-Whitney test, in case 
of data that did not follow a Gaussian distribution, were used to compare age, age of onset, 
Clinical Dementia Rating (CDR) staging and the MMSE score of the different groups of 
patients. Contingency tables were used to compare genetic frequencies according to gender, 
age of onset (cut off patients with and without variations and <65 and the same with ≥65), 
MMSE class (defined from the score, with >22=0 and ≤22=1) and clinical outcome, following 
analysis with Fisher’s exact test. The software used for statistical analysis was GraphPad and 
the result is considered significant when p value <0.05 (Motulsky, 1999). 
 
 
Results 
Sequence variations in MT-CYB gene were found in 44 patients (Figure 1), from a 
total of 70 patients. We have found only one variation in 14 patients, 2 variations in 11 
patients, 3 variations in 10 patients, 4 variations in 7 patients and 5 variations in 2 patients.  
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Figure 1: Graphical representation of the percentage of variations found in the 
patients’ population under study. 
 
A total of 37 different sequence variations were found (Figure 2), 15 of these are non-
synonymous (41%) while 22 of these are synonymous (59%). Sequence variations are listed 
in Table 3. All variations were found in homoplasmy. 
 
 
Figure 2: Graphical representation of the percentage of the type of variations 
identified in the patients’ population under study. 
 
63% 
37% 
Patients with variations 
Patients whitout variations  
41% 
59% 
Non-synonymous 
Synonymous 
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The majority of the variations identified were found in MITOMAP database: 25 have 
been described as “polymorphism”, 10 as “polymorphism” and “somatic mutation”. Two 
sequence variations were not reported in MITOMAP (m.15073C>T; m.15127C>T), being 
considered as “novel”. 
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Table 3: mtDNA sequence variations of MT-CYB gene identified in FTLD patients.  
Sequence 
Variation 
Aminoacid 
Change 
Reported in MITOMAP 
Frequency 
in the 
sample 
(n=70) 
Frequency in 
published 
sequences n=5140 
(Pereira et al., 2009) 
m.14766C>T  Thr7Ile Polymorphism 0.47 0.80 
m.14798T>C Phe18Leu Polymorphism 0.16 0.07 
m.14866C>T Synonymous Polymorphism; Pancreatic 
cancer cell line 
0.03 0.001 
m.14869G>A Synonymous Polymorphism; Breast tumor 0.01 0.004 
m.14872C>T  Synonymous Polymorphism 0.03 0.006 
m.14883C>T Thr46Ile Polymorphism 0.01 0.0002 
m.14902C>T Synonymous Polymorphism 0.01 0.001 
m.14905G>A Synonymous Polymorphism 0.03 0.04 
m.14927A>G Thr61Ala Polymorphism 0.01 0.007 
m.14979T>C Ile78Thr Polymorphism 0.01 0.01 
m.15013A>G Synonymous Polymorphism; Pituitary 
adenoma 
0.01 NR 
m.15043G>A Synonymous Polymorphism; MDD-
associated 
0.04 0.28 
m.15073C>T Synonymous NOVEL 0.01 NR 
m.15097T>C Synonymous Polymorphism 0.01 0.0004 
m.15127C>T Synonymous NOVEL 0.01 NR 
m.15164T>C Phe140Leu Polymorphism 0.01 0.0002 
m.15217G>A Synonymous Polymorphism 0.04 0.01 
m.15244A>G Synonymous Polymorphism 0.01 0.01 
m.15257G>A Asp171Asn Polymorphism; LHON 0.06 0.007 
m.15299T>C Synonymous Polymorphism 0.01 0.001 
m.15301G>A Synonymous Polymorphism; Tumor 0.01 0.37 
m.15314G>A Ala190Thr Polymorphism 0.03 0.007 
m.15452C>A Leu236Ile Polymorphism 0.17 0.07 
m.15465T>C Met240Thr Polymorphism 0.01 0.0002 
m.15530T>C  Synonymous Polymorphism 0.01 0.006 
m.15607A>G Synonymous Polymorphism 0.03 0.04 
m.15616C>T Synonymous Polymorphism 0.01 0.0002 
m.15626C>T Synonymous Polymorphism 0.01 0.002 
m.15629T>C Synonymous Polymorphism 0.01 0.009 
m.15679A>G Synonymous Polymorphism 0.01 0.0008 
m.15693T>C Met316Thr Polymorphism; Possibly 
LVNC cardiomyopathy-
associated; Breast cancer 
0.03 0.01 
m.15784T>C Synonymous Polymorphism; Pancreatic 
cancer cell line 
0.01 0.04 
m.15812G>A Val356Met Polymorphism; LHON; 
Breast cancer 
0.03 0.005 
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m.15833C>T Synonymous Polymorphism 0.01 0.005 
m.15848A>G Thr368Ala Polymorphism 0.01 0.001 
m.15884G>A  Ala380Thr Polymorphism 0.01 0.01 
m.15884G>C Ala380Pro Polymorphism; Pancreatic 
cancer cell line 
0.01 0.01 
 NR: Not reported in published sequences (Pereira et al., 2009). 
 
The results of in silico analysis performed in the non-synonymous variations are 
presented on Table 4, suggesting that there are 5 alterations with possible impact in protein 
function. The tests scores that predict an impact in protein function are highlighted.
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Table 4: The in silico analysis results for the non-synonymous variations found in FTLD patients. 
* Sequence is not available in all species (Caenorhabditis elegans). 
# Sequence is not available in all species (Mus Musculus, Bos Taurus, Xenopus laevis, Strongylocentrotus purpuratus, Drosophilla 
melanogaster, Caenorhabditis elegans). 
Sequence 
Variation 
Amino acid 
Change 
Poly-Phen 2.2.2 SIFT Provean Mutation Assessor 
Evolutionary 
conservation 
Score Prediction Score Prediction Score Prediction Score Prediction Gene Amino acid 
m.14766C>T  Thr7Ile 0 BENIGN 0.24 TOLERATED -2.35 Neutral -2.49 Neutral 77%* 36% 
m.14798T>C Phe18Leu 0 BENIGN 1 TOLERATED -3.09 Neutral -0.49 Neutral 86% 64% 
m.14883C>T Thr46Ile 0 BENIGN 1 TOLERATED 1.94 Neutral -1.425 Neutral 29% 29% 
m.14927A>G Thr61Ala 0 BENIGN 0.04 AFECT PROTEIN 
FUNCTION 
-1.93 Neutral 2.95 Medium damage 79% 64% 
m.14979T>C Ile78Thr 0 BENIGN 0.07 TOLERATED -2.50 Deleterious 2.11 Medium damage 93% 29% 
m.15164T>C Phe140Leu 0.012 BENIGN 0.18 TOLERATED -4.85 Deleterious 3.42 Medium damage 100% 100% 
m.15257G>A Asp171Asn 0.001 BENIGN 0.45 TOLERATED -3.56 Deleterious 2 Medium damage 86% 86% 
m.15314G>A Ala190Thr 0 BENIGN 0.35 TOLERATED -1.67 Neutral 1.12 Low 43% 43% 
m.15452C>A Leu236Ile 0.029 BENIGN 0.55 TOLERATED -0.79 Neutral 0.68 Neutral 57% 71% 
m.15465T>C Met240Thr 0.987 PROBABLY 
DAMAGING 
0.02 AFECT PROTEIN 
FUNCTION 
0.23 Neutral 0.42 Neutral 86% 57% 
m.15693T>C Met316Thr 0 BENIGN 0.61 TOLERATED 1.04 Neutral -0.425 Neutral 57% 50% 
m.15812G>A Val356Met 0.004 BENIGN 0.15 TOLERATED -0.73 Neutral 1.57 Low 57% 57% 
m.15848A>G Thr368Ala 0 BENIGN 0.31 TOLERATED -0.46 Neutral 0.435 Neutral 86% 29% 
m.15884G>A  Ala380Thr 0 BENIGN 1 TOLERATED -0.01 Neutral -0.345 Neutral 18% 29%# 
m.15884G>C Ala380Pro 0.167 BENIGN 0.22 TOLERATED -0.30 Neutral 0.695 Neutral 18% 29%# 
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The results of the evolutionary conservation analysis for missense alterations, with location of 
the substituted amino acid position are described in Figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Aligned sequences for the non-synonymous variations in MT-CYB gene. 
 
Thr7Ile Thr46Ile Phe18Leu Thr61Ala Ile78Thr 
Phe140Leu Asp171Asn Ala190Thr Leu236Ile Met240Thr 
Met316Thr Val356Met Thr368Ala Ala380Thr Ala380Pro 
Page 23 of 56 
For the synonymous variations identified in FTLD patients, only evolutionary 
conservation analysis was performed and the results are listed in Table 5. The novel variations 
found are highlighted in red at the table. 
 
 
Table 5: Evolutionary conservation performed in synonymous variations. 
Sequence Variation 
Evolutionary conservation 
Gene Amino acid 
m.14866C>T 71% 93% 
m.14869G>A 7% 100% 
m.14872C>T 50% 71% 
m.14902C>T 36% 100% 
m.14905G>A 21% 93% 
m.15013A>G 50% 57% 
m.15043G>A 7% 86% 
m.15073C>T 50% 43% 
m.15097T>C 21% 43% 
m.15127C>T 50% 100% 
m.15217G>A 23% 100% 
m.15244A>G 43% 93% 
m.15299T>C 50% 93% 
m.15301G>A 14% 93% 
m.15530T>C 14% 93% 
m.15607A>G 93% 100% 
m.15616C>T 21% 100% 
m.15626C>T 79% 100% 
m.15629T>C 29% 43% 
m.15679A>G 79% 100%* 
m.15784T>C 29% 100% 
m.15833C>T 57% 79% 
* Sequence is not available in all species (Caenorhabditis elegans). 
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Statistical analysis was performed to test the correlation according to the 
presence/absence of MT-CYB gene variations and different demographic or clinical variables 
of the patients (age, age of onset, gender, CDR stage and MMSE class and clinical outcome). 
The p values are shown in Table 6. 
Significant results are observed for age (p=0.0214), CDR stage (p=0.0183) and 
MMSE (p=0.0041).  
The correlation between patients who has MT-CYB variations and the gender, age of 
onset (cut off 65 years), MMSE class and clinical outcome, compared to the correlation 
between patients without alterations and the clinical characteristics referred are represented in 
Table 7. 
The results found were not significant for all variables analyzed (p value >0.05). 
 
Table 6: Statistical analysis using t-test or Mann-Whitney test to evaluate if variations in MT-
CYB affect age of the patients, age of onset of disease, CDR staging or the MMSE score. 
 
  
p value 
T-test Mann-Whitney 
Age 0.0214   
Age of onset 0.0514   
CDR stage   0.0183 
MMSE score   0.0041 
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Table 7: Contingency analysis using Fisher’s exact test, sorting the patients by presence or 
absence of mtDNA variations in MTCYB gene and by gender, age of onset, MMSE class and 
clinical outcome (results not shown). 
 
  p value 
Gender 1.0000 
Age of onset* 1.0000 
MMSE class# 0.0585 
Clinical outcomeⱡ 0.4782 
* Cut off patients with and without variations and <65 and the same with ≥65. 
# MMSE class is defined from the score, with >22=0 and ≤22=1. 
ⱡ bvFTD versus language variants. 
 
 
Discussion 
In the present study, a higher number of synonymous variations were found, 22 (59%), 
compared to non-synonymous variations, 15 (41%), as presented in Figure 2. Among 
synonymous variations, 2 are “NOVEL” (m.15073C>T; m.15127C>T), meaning that they are 
not reported in MITOMAP database (http://mitomap.org). These variations are present in only 
1 patient each one, with a frequency in the sample of 0.01 (Table 3). According to the 
evolutionary conservation analysis, m.15073C>T affects a nucleotide that is conserved in 
50% of the species and an amino acid conserved only in 43% of the species under study. On 
the other hand, m.15127C>T leads to an alteration of a nucleotide also conserved in 50% of 
the species; however, the corresponding amino acid is conserved in 100% of the species 
analyzed, meaning that it could have an important and vital role to the protein structure/ 
function. According to the “codon usage” database, the triplets that codify the same amino 
acid are not used with the same frequency; one is always preferred instead of another. In fact, 
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the frequency of the preference is already achieved, however there is not a clearly explanation 
for the fact. Concerning m.15073C>T, the frequency of codon usage is affected, from UAC 
(22.2) to UAU (12.9) and for m.15127C>T the frequency of codon usage is GCC (29.6) to 
GCU (14.0). The variation results in the choice of a codon that has a lower frequency of use. 
It could have an impact in the modulation of pathophysiological processes (Nakamura et al., 
2000). 
A total of 37 different variations were found, 15 of which lead to amino acid change in 
the mitochondrial CYT-B protein. In order to infer the possible pathogenicity of the variation, 
in silico analysis was performed and the results suggest that the variations that could have an 
impact in protein function are m.14927A>G, m.14979T>C, m.15164T>C, m.15257G>A, 
m.15465T>C, however some results of the different software tools are in disagreement (Table 
4), which may be explained by the differences in the parameters considered for analysis in 
each case. 
Regarding the variation m.14927A>G, it was found in 1 patient of our cohort (0.01) 
and it has a frequency of 0.007 (n=36) in published (n=5140) sequences (Pereira et al., 2009). 
This alteration results in the change of an amino acid threonine, polar, to an isoleucine, 
nonpolar, in position 7 of the protein, which possible indicates an impact in the protein 
function; only SIFT predicts this possible impact (score 0.04), Mutation Assessor predicts 
medium damage (score 2.95), but the result in Poly-Phen and Provean is benign. According 
to evolutionary conservation, the amino acid threonine is not totally conserved (63%). 
Nevertheless, it is interesting to notice that all the species in which the amino acid is 
conserved are mammals. In MITOMAP this variation has been reported associated with 
Parkinson’s disease, encephalomyopathy and hypertrophic cardiomyopathy. 
The m.14979T>C variation is classified as deleterious by Provean software (score -
2.50) and Mutation assessor predicts (score 2.11) a medium damage effect. However, the 
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change of a nonpolar isoleucine to a polar threonine, in position 78, is not enough to justify 
the results obtained in the software analyses. In addition, the amino acid is poorly conserved 
in other species and it is not likely to have the impact to alter the protein function. 
The m.15164T>C is predicted to alter the protein function by Provean, classified as 
deleterious (score 4.85), and by Mutation Assessor as medium damage (score 3.42). 
Concerning the evolutionary conservation, it is highly conserved in nucleotide sequence 
(100%) and in amino acid (100%). This variation changes an aromatic phenylalanine to a 
polar leucine on a highly conserved site of the protein, leading to a total modification in its 
chemical structure. Moreover, taking into account the low frequency in our sample, 0.0003 
(n=1) and in published sequences (n=5140), 0.0002 (n=1) (Grazina et al., 2006), it is likely 
that the alteration has a pathological significance. 
Nevertheless m.15257G>A has been reported (Howell et al., 1993) in MITOMAP 
associated with Leber's hereditary optic neuropathy (LHON), the results suggest that it does 
not have an impact in protein function. This variation has a frequency of 0.06 (n=4) in our 
sample, much higher than in published sequences (37 out of 5140, 0.007) (Pereira et al., 
2009). According to the present analysis, it appears to have a benign character by Poly-Phen 
and SIFT. It is classified as deleterious (score -3.56) by Provean, as medium damage by 
Mutation Assessor (score 2) and the amino acid is 86% conserved in other species. However, 
the change of a polar aspartate to an asparagine (Asp171Asn), which is equally polar, 
suggests that it should not have major impact in functional outcome.  
Another variation is m.15465T>C that changes a polar and sulphureted methionine to 
a nonpolar threonine in position 240 and it could be a deleterious variation. This hypothesis is 
supported by the result found in Poly-Phen (score 0.987) and SIFT (score 0.02), predicting an 
impact in protein function. According to the evolutionary conservation analysis, this amino 
acid is highly conserved in mammals. In addition, it reveals a low frequency in our sample, 
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0.01 (n=1), but much lower in published sequences (n=5140), 0.0002 (n=1) (Pereira et al., 
2009), decreasing the possibility of being a polymorphism and corroborates the major impact 
in protein function. In MITOMAP, it is not reported in association with pathologies. 
All the non-synonymous variations were already reported in MITOMAP database; 
however, only a few are reported in association with pathologies. 
 On the other hand, it is important to complete the study with the results of statistical 
analysis. Interesting data emerged from the present study, namely the significant results 
concerning the analysis of CDR staging (p=0.0183) and MMSE score (p=0.0041), revealing a 
positive correlation with the presence of MT-CYB variations in FTLD patients, which 
reinforces the hypothesis of genetic variations contributing to the development of FTLD. 
Since the results are only referred to diagnostic scales, it is likely that those alterations are 
involved in the pathophysiology of particular disease forms. 
A positive correlation between the presence of MT-CYB variations and particular 
patients’ characteristics, such as age has also been found. However, it does not have a 
correspondence to age of onset, which does not allow taking any clearly conclusion. 
Nevertheless, this hypothesis points towards the existence of factors related to age, but 
apparently independent of disease onset for this gene. 
 In order to better understand the significance of the results, it would be interesting the 
analysis of a study group of healthy age matched subjects, as a control group for the genetic 
investigation performed. 
Furthermore, a functional study of altered complex III and cytochrome b could help to 
prove the possible pathogenicity of these genetic variations. 
 On the other hand, it is relevant to mention that the sample was obtained from the 
peripheral blood leukocytes. Taking into account that the alterations were found in 
homoplasmy, the results could be extrapolated to the brain tissue. However, there might be 
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somatic mutations in heteroplasmy in the brain that are not present in the blood cells (Grazina 
et al., 2003). 
Most of the alterations identified have been previously described as polymorphisms. 
However, we cannot exclude the possibility of these variations being involved in the 
pathogenesis of FTLD. It should be noted the fact that a set of changes, which, when taken 
separately, are not pathogenic, but along with other changes, either in other mitochondrial 
genes, nuclear genes and environmental factors, they could cause MRC dysfunction (Grazina 
et al., 2006). It is also important to understand the cellular processes that lead to 
neurodegeneration (Hales & Hu, 2013), which is highly complex. 
Recently, remarkable progresses have been made regarding the understanding of the 
genetic causes, molecular basis, and neuropathological features of FTLD. Most common 
genetic alterations that cause FTLD have been discovered and the major pathological proteins 
have been identified (Riedl et al., 2014). 
Although significant progress has occurred in diagnosing FTLD, challenges remain in 
accurately identifying patients with the high sensitivity and specificity at the earliest possible 
stage. Establishing measures that elucidate the underlying cellular process responsible for 
specific FTLD pathology will be essential for developing successful therapeutic trials (Hales 
& Hu, 2013). And variations in mtDNA may play an important role. 
In order to reinforce the data obtained in this study is important to carry out further 
studies that allow us to understand the possible existence of a relationship between mtDNA 
variations and the pathophysiology of FTLD. 
 
Conclusion 
The present study reports new data concerning mtDNA variations in FTLD patients. 
The results did not show any variation that is clearly pathogenic, but some of them have a 
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high probability of contributing to alter the normal MRC function, together with other factors, 
can cause mitochondrial dysfunction, which is a central event previously reported in 
neurodegeneration. These variations are m.14927A>C; m.15164T>C; m.15465T>C. In silico 
analysis suggest a major impact in protein function, as well as the highly conservation in 
species and low frequency in patients. 
On the other hand, the statistical analysis for evaluating the correlation of patients’ 
characteristics, like CDR staging and MMSE score, with the presence/absence of genetic 
variants, revealed significant results: a positive correlation between patients that have 
variations in MT-CYB and their lower CDR staging and MMSE scores. 
 In addition, two “novel” synonymous variations were found that have not been 
reported in MITOMAP database. It is not clear if they are 100% benign, or if the substitution 
of a nucleotide, apparently codifying an amino acid that have the same structural 
characteristics of the original, would functionally remains exactly the same protein? 
According to the “Mitochondrial cascade hypothesis” (Swerdlow & Khan, 2004), 
polymorphic variations in MRC subunits encoding genes lead to MRC efficiency and increase 
in mitochondrial ROS production, that correlates with mtDNA damage. Furthermore, somatic 
mtDNA mutations decrease MRC and OXPHOS efficiency, enhancing ROS production. 
Thus, changes in mtDNA may affect the age of onset of a particular disease, 
contributing to the neurodegenerative process, which may be related to the impairment of 
MRC (Grazina et al., 2006). Additionally, mutations in mtDNA can have a cumulative effect, 
increasing the probability of developing an energy failure of the MRC (Grazina et al., 2004). 
 Our study is original and it represents an important contribution to the understanding 
of this complex disease and to the achievement of successful diagnosis and treatment of these 
patients. 
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Appendix 1: Patients’ characterization and data from genetic analysis of MT-CYB gene. 
Patient Gender Age Diagnostic 
Age of 
onset 
CDR 
stage 
MMSE 
score 
mtDNA 
variations 
1 M 73 bvFTD 73 1 28 
m.14766C>T 
m.15257G>A 
m.15452C>A 
m.15530T>C 
m.15812G>A 
2 F 77 bvFTD 73 3 10 None 
3 F 69 bvFTD 69 1 19 None 
4 F 68 bvFTD 66 2 15 None 
5 M 64 bvFTD 62 0.5 28 m.14766C>T 
6 M 45 bvFTD 40 3 7 None 
7 M 75 bvFTD 64 1 27 
m.14766C>T 
m.14798T>C 
m.15452C>A 
8 F 49 avPPA 48 1 30 
m.14766C>T 
m.14798T>C 
m.15452C>A 
m.15616C>T 
9 F 78 bvFTD 78 1 28 
m.14766C>T 
m.15073C>T 
10 M 58 bvFTD 44 3 6 None 
11 M 43 CBS 42 1 22 None 
12 M 65 bvFTD 63 0.5 29 m.15833C>T 
13 M 64 bvFTD 60 1 22 
m.14766C>T 
m.14798T>C 
m.15452C>A 
14 M 71 bvFTD 68 0.5 30 
m.14766C>T 
m.15884G>C 
15 M 70 bvFTD 67 1 25 m.14869G>A 
16 F 81 bvFTD 75 2 13 None 
17 F 77 bvFTD 64 1 21 
m.14766C>T 
m.15043G>A 
18 M 43 bvFTD 43 2 16 None 
19 F 53 bvFTD 52 3 0 None 
20 F 65 bvFTD 63 3 1 None 
21 F 54 bvFTD 53 2 18 m.15465T>C 
22 M 54 svPPA 52 1 21 
m.14766C>T  
m.14866C>T 
m.15693T>C 
23 F 71 bvFTD 67 3 14 
m.14766C>T  
m.14798T>C 
m.15127C>T 
24 M 51 bvFTD 51 1 25 m.14872C>T 
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25 M 60 avPPA 58 3 9 
m.14766C>T  
m.14798T>C 
26 M 69 bvFTD 54 0.5 28 
m.14766C>T  
m.14798T>C 
m.15097T>C 
m.15452C>A 
27 F 64 bvFTD 63 1 25 
m.14766C>T 
m.14798T>C 
m.15626C>T 
28 F 65 bvFTD 64 3 11 
m.14766C>T 
m.15314G>A 
29 M 46 svPPA 41 3 10 None 
30 M 65 bvFTD 63 1 29 m.15164T>C 
31 M 61 bvFTD 56 2 12 None 
32 M 67 bvFTD 59 1 27 
m.14766C>T 
m.15217G>A 
33 M 72 bvFTD 69 2 13 None 
34 M 66 bvFTD 63 1 29 
m.14766C>T 
m.15257G>A 
m.15452C>A 
m.15679A>G 
35 M 68 bvFTD 67 1 27 
m.14766C>T 
m.15257G>A 
m.15452C>A 
m.15812G>A 
36 M 70 bvFTD 69 1 20 
m.14766C>T  
m.15043G>A 
37 F 82 bvFTD 78 1 20 
m.14766C>T 
m.15314G>A 
38 F 69 avPPA 56 1 13 
m.14766C>T  
m.14905G>A 
m.15452C>A  
m.15607A>G 
39 F 62 bvFTD 59 2 17 None 
40 F 74 bvFTD 72 1 15 m.14766C>T 
41 F 48 bvFTD 47 3 0 m.14883C>T 
42 M 64 bvFTD 61 1 24 None 
43 M 74 bvFTD 73 2 16 None 
44 F 59 bvFTD 53 3 0 m.14872C>T 
45 F 59 bvFTD 55 3 0 None 
46 F 59 bvFTD 57 1 18 m.15013A>G 
47 F 60 bvFTD 56 1 15 None 
48 F 65 avPPA 62 3 4 None 
49 F 71 bvFTD 68 2 12 
m.14766C>T  
m.14927A>G 
50 F 58 CBS 58 1 18 None 
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51 F 59 bvFTD 58 2 16 
m.14766C>T 
m.15244A>G  
m.15301G>A  
m.15629T>C 
m.15784T>C 
52 F 54 bvFTD 54 1 26 None 
53 F 55 bvFTD 54 1 22 
m.14766C>T 
m.14798T>C 
m.15452C>A 
54 F 54 bvFTD 50 2 19 
m.14766C>T 
m.14798T>C 
m.15452C>A 
55 F 74 bvFTD 73 1 17 
m.14766C>T  
m.14798T>C 
m.15217G>A  
m.15452C>A 
56 F 75 bvFTD 72 1 20 None 
57 F 62 CBS 60 1 20 None 
58 F 49 bvFTD 48 0.5 30 m.14979T>C 
59 F 50 bvFTD 50 2 17 m.14766C>T 
60 F 74 bvFTD 69 2 15 
m.14766C>T  
m.14866C>T 
m.15693T>C 
61 F 75 bvFTD 74 1 27 None 
62 F 46 bvFTD 43 1 22 
m.14766C>T 
m.15884G>A 
63 F 81 bvFTD 79 1 21 
m.14766C>T 
m.15043G>A 
m.15299T>C 
64 F 66 bvFTD 60 3 16 
m.14766C>T  
m.14798T>C 
m.15257G>A 
65 M 48 bvFTD 45 2 13 m.15848A>G 
66 M 38 bvFTD 34 1 25 None 
67 M 54 CBS 53 3 0 
m.14902C>T 
m.15217G>A 
68 M 70 bvFTD 68 1 22 
m.14766C>T  
m.14905G>A 
m.15452C>A  
m.15607A>G 
69 M 76 bvFTD 70 1 28 m.14766C>T 
70 M 59 bvFTD 56 1 21 None 
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Appendix 2: Guide for Authors from “Genes, Brain and Behavior” 
 
Author Guidelines 
Last update: July 2014 
 
Effective with the 2014 volume, this journal will be published in an online-only format. 
We will continue to offer online publication and online reproduction of colour figures free of 
charge. We envision that the transition to online only will allow us to offer our authors an 
improved peer review and production service but if you do have any questions or concerns 
please feel free to contact us at gbb@wiley.com. 
 
Electronic submission of manuscripts 
 
Authors should submit online to http://mc.manuscriptcentral.com/g2b separate files for the 
text (as a .doc, .docx or .rtf Word document) and each figure (important: figure files should be 
no more than 2000x2000 pixels for review purposes), particularly for high quality images so 
that these can be reviewed by the referees. Alternatively, authors can submit a single .doc, 
.docx or .rtf file with embedded images (from which a PDF file will automatically be created 
upon upload). No hard copies are necessary at submission stage. The review process is 
entirely electronic-based and therefore facilitates faster reviewing of manuscripts. Authors 
who are unable to submit their manuscript online should contact the Editorial Office for 
assistance at the following address: 
 
Genes, Brain and Behavior - Editor-in-Chief 
E-mail: EIC-G2B@wiley.com 
 
Authors may include supporting information for the referees' inspection. The manuscript 
should be accompanied by a cover letter from the corresponding author, who should be 
clearly identified on the title page, and the cover letter should clearly indicate which of the 
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authors (if any) are members of the International Behavioural and Neural Genetics Society 
(IBANGS). (The corresponding author for editorial purposes need not be the senior author, 
nor the person to whom correspondence is addressed after publication). Statements of equal 
contribution from more than one author are permitted. Authors are requested to upload 
suggestions for 4 referees and may also request the exclusion of up to 4 persons as possible 
referees, although these suggestions will not necessarily be followed. 
 
If the manuscript includes personal communications, please provide a written statement of 
permission from any person who is quoted. Printouts of e-mail permission messages are 
acceptable. 
 
The manuscript should be an original work, not published before and not being considered for 
publication elsewhere. For any material not owned by the author, permission from the 
copyright holder should have been obtained. 
 
Figure files should be no more than 2000x2000 pixels for review purposes. However, upon 
acceptance, figures should be re-supplied as high resolution TIFF or EPS files. More 
information on our digital illustration standards can be obtained here. 
 
Pre-submission English-language editing 
 
Authors for whom English is a second language may choose to have their manuscript 
professionally edited before submission to improve the English. A list of independent 
suppliers of editing services can be found here. All services are paid for and arranged by the 
author, and use of one of these services does not guarantee acceptance or preference for 
publication. 
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Cover Letter 
 
Authors should upload a cover letter in a separate file, which should contain the following 
information: 
(i) An explicit statement that the manuscript (or parts thereof) has not been published before 
and is not being considered for publication elsewhere; 
(ii) The word counts of the Abstract, Introduction, and Discussion; 
(iii) A justification if the manuscript may be expected to exceed 10 printed journal pages 
(about 7000 words in total including references, tables, etc); 
(iv) Which of the authors, if any, are members in good standing (i.e., current on their dues 
payments) of the International Behavioural and Neural Genetics Society (IBANGS). 
 
It should be noted that the size of manuscripts intended for publication in supplements will be 
determined in consultation with the organizers of the supplement and are not subjected to any 
other word- and page limits. 
 
License Agreements 
 
If your paper is accepted, the author identified as the formal corresponding author for the 
paper will receive an email prompting them to login into Author Services; where via the 
Wiley Author Licensing Service (WALS) they will be able to complete the license agreement 
on behalf of all authors on the paper. 
 
For authors choosing OnlineOpen 
 
OnlineOpen is available to authors of articles who wish to make their article open access. 
With OnlineOpen the author, their funding agency, or institution pays a fee to ensure that the 
article is made available to non-subscribers upon publication via Wiley Online Library, as 
well as deposited in PubMed Central and PMC mirror sites. In addition to publication online 
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via Wiley Online Library, authors of OnlineOpen articles are permitted to post the final, 
published PDF of their article on a website, institutional repository, or other free public 
server, immediately on publication. 
 
If you want your article to be open access please choose the appropriate license agreement 
when you log in to Wiley’s Author Services system. Click on ‘Make my article OnlineOpen’ 
and choose the appropriate license by clicking on ‘Sign license agreement now’ when you log 
in to Wiley’s Author Services system. 
 
If the OnlineOpen option is selected the corresponding author will have a choice of the 
following Creative Commons License Open Access Agreements (OAA): 
 
Creative Commons Attribution License OAA 
Creative Commons Attribution Non-Commercial License OAA 
Creative Commons Attribution Non-Commercial -NoDerivs License OAA 
 
To preview the terms and conditions of these open access agreements please visit the 
Copyright FAQs hosted on Wiley Author Services 
http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit 
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html. 
 
If you select the OnlineOpen option and your research is funded by The Wellcome Trust and 
members of the Research Councils UK (RCUK) or the Austrian Science Fund (FWF) you will 
be given the opportunity to publish your article under a CC-BY license supporting you in 
complying with your Funder requirements. For more information on this policy and the 
Journal’s compliant self-archiving policy please visit: 
http://www.wiley.com/go/funderstatement. 
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For authors signing the Copyright Transfer Agreement 
 
If the OnlineOpen option is not selected the corresponding author will be presented with the 
copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be 
previewed in the samples associated with the Copyright FAQs below: 
 
CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp 
 
NIH-funded authors and G2B 
 
The NIH mandates grantees to deposit their peer-reviewed author manuscripts in PubMed 
Central, to be made publicly available within 12 months of publication. The NIH mandate 
applies to all articles based on research that has been wholly or partially funded by the NIH 
and that are accepted for publication on or after April 7, 2008. In order to help authors comply 
with the NIH mandate, for papers accepted for publication in G2B, Wiley Blackwell will post 
the accepted manuscript (incorporating all amendments made during peer review, but prior to 
the publisher's copy-editing and typesetting) of articles by NIH grant-holders to PubMed 
Central at the point of acceptance by the journal. This version will then be made publicly 
available in PubMed Central 12 months after publication. Following the deposit Wiley 
Blackwell authors will receive further communications from the NIH with respect to the 
submission. For further information, see here. 
 
If authors wish to make their final published article openly accessible and without a 12 month 
embargo, they can choose to publish via the OnlineOpen service. Wellcome Trust and HHMI 
grantees can find out further information here. 
 
Author Services 
 
Online production tracking is now available for your article through Wiley Blackwell's 
Author Services. This enables authors to track their article - once it has been accepted - 
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through the production process to publication online. Authors can check the status of their 
articles online and choose to receive automated e-mails at key stages of production. The 
author will receive an e-mail with a unique link that enables them to register and have their 
article automatically added to the system. Please ensure that a complete e-mail address is 
provided when submitting the manuscript. Visit this page for more details on online 
production tracking and for a wealth of resources including FAQs and tips on article 
preparation, submission and more. 
 
Accepted Articles 
 
Genes, Brain and Behavior offers Accepted Articles. Accepted Articles have been accepted 
for publication and undergone full peer review but have not been through the copyediting, 
typesetting, pagination and proofreading process. Accepted Articles are published online a 
few days after final acceptance, appear in PDF format only, are given a Digital Object 
Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. 
 
Page Charges 
 
Articles longer than 7 pp. when in proof will be subject to a page charge for excess journal 
pages above that limit, at GBP50 per page above the 7-pp. limit. For IBANGS members, the 
charge is GBP50 for each page in excess of 10 pp. An invoice will be sent to authors for these 
charges upon publication of their article in an issue. Authors will have to provide a 
justification in their cover letters in case their manuscripts may be expected to exceed 10 
printed journal pages (approximately 7000 words in total). Review articles will not incur page 
charges. 
 
Author material archive policy 
 
Please note that unless specifically requested, Wiley Blackwell will dispose of all hardcopy or 
electronic material submitted two months after publication. If you require the return of any 
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material submitted, please inform the editorial office or production editor as soon as possible 
if you have not yet done so. 
 
Types of papers accepted 
 
Research Articles must describe significant and original observations and provide sufficient 
detail so that the observations can be critically evaluated and, if necessary, repeated. Articles 
dealing primarily with techniques, either describing a new technique or providing a review of 
the use of an existing technique, should be submitted as Techniques. 
 
For human studies, the characteristics of subjects should be sufficiently described (including 
ethnicity, age). Authors of human genetic association studies are strongly encouraged to 
consult the journal's guidelines prior to submission. 
 
Proposals for Reviews are welcome; please contact the Editor in Chief directly at the Editorial 
Office address provided above. Review proposals should include a full-page summary of the 
proposed contents with key references. Reviews are selected for their broad general interest; 
all are refereed by experts in the field who are asked to comment on issues such as timeliness, 
general interest and balanced treatment of controversies, as well as on scientific accuracy. 
Reviews should take a broad view of the field rather than merely summarizing the authors 
own previous work, so extensive citation of the authors own publications is discouraged. 
 
Genes, Brain and Behavior also publishes Commentaries, Debates, Letters to the Editor (on 
articles published in the Journal) and Book Reviews. Debates are generally two separate 
papers reflecting opposing views on a controversial issue. Commentaries are opinion pieces 
on topics of general interest to the behavioral neurogenetics community. They need not be 
confined to purely scientific topics; policy issues and social implications of behavioral and 
neural genetics may also be covered. Suggestions for Debates, Commentaries and Book 
Reviews are welcome. Because Genes, Brain and Behavior offers very rapid online 
publication for all accepted papers and authors are urged to be as succinct as possible, there 
are no 'Rapid Communications' or 'Short Communications' categories. 
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Referrals to the journal Brain and Behavior 
 
This journal works together with Wiley’s Open Access Journal, Brain and Behavior, to enable 
rapid publication of good quality research that is unable to be accepted for publication by our 
journal. Authors will be offered the option of having the paper, along with any related peer 
reviews, automatically transferred for consideration by the Editor of Brain and Behavior. 
Authors will not need to reformat or rewrite their manuscript at this stage, and publication 
decisions will be made a short time after the transfer takes place. The Editor of Brain and 
Behavior will accept submissions that report well-conducted research which reaches the 
standard acceptable for publication. Accepted papers can be published rapidly: typically 
within 15 days of acceptance. Brain and Behavior is a Wiley Open Access journal and article 
publication fees apply. For more information please go to www.brain-behavior.com. 
 
Peer Review Scorecard Pilot 
 
Genes, Brain and Behavior is participating in Wiley's pilot of transferable peer review in 
which reviewers complete a standard scorecard in addition to their usual review. Authors of 
original research articles rejected with completed scorecards will be invited to transfer the 
manuscript, reviews, and scorecard to any of the other journals participating in the pilot. 
Authors will have the opportunity to revise their manuscript according to the review 
comments prior to transfer if they wish to do so. A list of the participating journals and more 
information about the pilot can be found here. We believe that this system of preserving 
original peer review for the next journal's use will decrease repetitious review, save authors, 
reviewers, and editors valuable time and significantly increase the speed to publication for 
many papers. 
 
Organization of Research Articles 
 
Authors should pay special attention to the presentation of their findings so that they may be 
communicated clearly. Technical jargon should be avoided as much as possible and clearly 
explained where its use is unavoidable. Abbreviations should also be kept to a minimum, 
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particularly those that are not standard. The background and hypotheses underlying the study, 
as well as its main conclusions, should be clearly explained. Titles and abstracts especially 
should be written in language that will be readily intelligible to any scientist. 
 
Title: must be concise and contain no more than 100 characters including spaces. The title 
page should include a running title of no more than 50 characters; 5-10 key words, complete 
names of institutions for each author, and the name, address, telephone number, fax number 
and e-mail address for the corresponding author. The title page should also include the date of 
submission (or revision/resubmission) and the numbers of words in the Abstract, Introduction, 
and Discussion sections of the paper. 
 
Abbreviations: Genes, Brain and Behavior adheres to the conventions outlined in Units, 
Symbols and Abbreviations: A Guide for Medical and Scientific Editors and Authors. Non-
standard abbreviations must be used three or more times and written out completely in the 
text when first used. 
 
Abstract: is limited to 250 words in length and should not contain abbreviations. References 
must be cited in full. 
 
Main Text 
 
Introduction: should be focused, outlining the historical or logical origins of the study and not 
summarize the results, and is limited to 500 words in length; exhaustive literature reviews are 
not appropriate. 
 
Materials and Methods: must contain sufficient detail such that, in combination with the 
references cited, all experiments reported can be fully reproduced. As a condition of 
publication, authors are required to make materials and methods used freely available to 
academic researchers for their own use. This includes antibodies and the constructs used to 
make transgenic animals, although not the animals themselves. Papers reporting protein or 
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DNA sequences and crystallographic structure determinations will not be accepted without a 
Genbank or Brookhaven accession number, respectively. Other supporting data sets must be 
made available on the publication date from the authors directly. 
 
(i) Experimental Subjects: When human subjects are used, manuscripts must be accompanied 
by a statement that the experiments were undertaken with the understanding and written 
consent of each subject. Authors should be aware of the Code of Ethics of the World Medical 
Association (Declaration of Helsinki), which has been printed in the British Medical Journal 
(18 July 1964). 
When experimental animals are used the methods section must clearly indicate that adequate 
measures were taken to minimize pain or discomfort. Experiments should be carried out in 
accordance with the Guidelines laid down by the National Institute of Health (NIH) in the 
USA regarding the care and use of animals for experimental procedures or with the European 
Communities Council Directive of 24 November 1986 (86/609/EEC). 
All studies using human or animal subjects should include an explicit statement in the 
Material and Methods section identifying the review and approval committee for each study, 
if applicable. Editors reserve the right to reject papers if there is doubt as to whether 
appropriate procedures have been used. 
(ii) Suppliers: Suppliers of materials should be named and, with the exception of well-known 
suppliers, such as Sigma, Kodak and Zeiss, their location (town, state/county, country) 
included. 
 
Results: should present the observations with minimal reference to earlier literature or to 
possible interpretations. 
 
Discussion: may usefully start with a brief summary of the major findings, but repetition of 
parts of the abstract or of the results section should be avoided. The Discussion section is 
limited to 1500 words. 
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References: should follow the Harvard style of references, outlined below, and should be 
cited in the text as: 'White (2001) has shown...' or '...as shown earlier (Blanc & White, 1999; 
Weiss et al., 2000)'. When different groups of authors with the same first author and year of 
publication occur, they should be cited thus, Weiss et al. (2000a,b), to differentiate clearly 
between them. Multiple citations should be listed alphabetically by author surname. 
References should be listed at the end of the manuscript in alphabetical order according to the 
name of the first author and chronologically where several papers by the same author are 
listed. The list of references should include only articles that have been published or are 
currently in press. In press manuscripts that are necessary to understand and evaluate the 
submitted manuscript must be included at the time of submission. In all cases, the full list of 
authors should be provided, and journal titles should be abbreviated following Index Medicus. 
Published conference abstracts and URLs for web sites should be cited parenthetically in the 
text, not in the reference list. Grant details and acknowledgements are not permitted as 
numbered references. 
 
We recommend the use of a tool such as EndNote or Reference Manager for reference 
management and formatting. 
EndNote reference styles can be searched for here: 
http://www.endnote.com/support/enstyles.asp 
 
Reference Manager reference styles can be searched for here: 
http://www.refman.com/support/rmstyles.asp 
 
An adapted profile for G2B can be downloaded here. 
 
Journal Article 
Podhorna, J. & Brown, R.E. (2002) Strain differences in activity and emotionality do not 
account for differences in learning and memory performance between C57BL/6 and DBA/2 
mice. Genes Brain Behav 1, 96-110. 
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Article in Book 
Katz, D.I. (1997) Traumatic brain injury. In Mills, V.M., Cassidy, J.W. & Katz, D.I. (eds), 
Neurologic Rehabilitation. A Guide to Diagnosis, Prognosis and Treatment Planning. 
Blackwell Science Ltd, Oxford, pp. 105-143. 
 
Complete Book 
Matthews, G.G. (1997) Neurobiology. Blackwell Science Ltd, Oxford. 
 
Symposia contributions should take a similar format to books, including the place and date of 
the meeting, the name and location of the organizer/publisher, both overall and contribution 
titles, all authors and Editors names, and page number(s): 
Fuss, S.H., Çelik, A. & Korsching, S.I. (2001) Levels of olfactory information processing in 
the zebrafish olfactory bulb. In Elsner, N. & Kreuzberg, G.W. (eds), Göttingen Neurobiology 
Report 2001. Proceedings of the 4th Meeting of the German Neuroscience Society 2001, Vol. 
II, 28th Göttingen Neurobiology Conference. Georg Thieme Verlag, Stuttgart, p. 474. 
 
Acknowledgements: should follow the References. Genes, Brain and Behavior requires that 
all sources of institutional, private and corporate financial support for the work within the 
manuscript must be fully acknowledged, and any potential conflicts of interest noted. Grant or 
contribution numbers may be acknowledged, and principal grant holders should be listed. 
Acknowledgments should be brief and should not include thanks to anonymous referees and 
editors. 
 
Figures: All figures should be planned to fit within either 1 column width (8.0 cm), 1.5 
column widths (13.0 cm) or 2 column widths (17.0 cm), and must be suitable for photocopy 
reproduction from the printed version of the manuscript. Lettering on figures should be in a 
clear, sans serif typeface (e.g. Helvetica); if possible, the same typeface should be used for all 
figures in a paper. After reduction for publication, upper-case text and numbers should be at 
least 1.5-2.0 mm high (10 point Helvetica). After reduction symbols should be at least 2.0-3.0 
mm high (10 point). In general, multi-part figures should be arranged as they would appear in 
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the final version. Reduction to the scale that will be used on the page is not necessary, but any 
special requirements (such as the separation distance of stereo pairs) should be clearly 
specified. 
 
Unnecessary figures and parts (panels) of figures should be avoided: data presented in small 
tables or histograms, for instance, can generally be stated briefly in the text instead. Figures 
should not contain more than one panel unless the parts are logically connected; each panel of 
a multipart figure should be sized so that the whole figure can be reduced by the same amount 
and reproduced on the printed page at the smallest size at which essential details are visible. 
 
Figures should be on a white background, and should avoid excessive boxing, unnecessary 
colour, shading and/or, decorative effects (e.g. 3-dimensional skyscraper histograms) and 
highly pixelated computer drawings. The vertical axis of histograms should not be truncated 
to exaggerate small differences. The line spacing should be wide enough to remain clear on 
reduction to the minimum acceptable printed size. 
 
Figures divided into parts should be labeled with a lower-case, boldface, roman letter, a, b, 
and so on, in the same typesize as used elsewhere in the figure. Lettering in figures should be 
in lower-case type, with the first letter capitalized. Units should have a single space between 
the number and the unit, and follow SI nomenclature or the nomenclature common to a 
particular field. Thousands should be separated by thin spaces (1 000). Unusual units or 
abbreviations should be spelled out in full or defined in the legend. Scale bars should be used 
rather than magnification factors, with the length of the bar defined in the legend rather than 
on the bar itself. In general, visual cues (on the figures themselves) are preferred to verbal 
explanations in the legend (e.g. broken line, open red triangles etc.). 
 
Please read our electronic artwork guidelines before submitting figures to ensure that they are 
in the correct format and resolution for print reproduction. 
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Colour figures 
 
If you have supplied figures in colour, these will appear as colour online free-of-charge. 
 
Permissions 
 
If all or parts of previously published illustrations are to be used, permission must be obtained 
from the copyright holder concerned. 
 
Figure Legends: should be a separate section of the manuscript, and should begin with a brief 
title for the whole figure and continue with a short description of each panel and the symbols 
used; they should not contain any details of methods. 
 
Tables: should be double-spaced with no vertical rulings, with a single bold ruling beneath the 
column titles. Units of measurements must be included in the column title. 
 
Supporting Information 
 
Supporting Information can be a useful way for an author to include important but ancillary 
information with the online version of an article. Examples of Supporting Information include 
additional tables, data sets, figures, movie files, audio clips, 3D structures, and other related 
nonessential multimedia files. Supporting Information should be cited within the article text, 
and a descriptive legend should be included. It is published as supplied by the author, and a 
proof is not made available prior to publication; for these reasons, authors should provide any 
Supporting Information in the desired final format. 
 
For further information on recommended file types and requirements for submission, please 
visit this link. 
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Publication Schedule 
 
Papers that do not conform to the general aims and scope of the journal will be returned 
immediately without review. All other manuscripts will be reviewed by experts in the field 
(generally two reviewers and an Editor). Genes, Brain and Behavior aims to forward 
reviewers comments and to inform the corresponding author of the result of the review 
process within 5 weeks of receipt of the manuscript by the Editorial Office. Revised 
manuscripts will be considered at the discretion of the editors, and may be subject to re-
review. Manuscripts will be considered for 'fast-track publication' under special circumstances 
after consultation with the Editor-in-Chief. 
 
Early View 
 
Genes, Brain and Behavior is covered by Wiley Blackwell's Early View service. Early View 
articles are complete full-text articles published online in advance of their publication in an 
issue. Articles are therefore available as soon as they are ready, rather than having to wait for 
the next scheduled issue and will also be included in PubMed as 'epub ahead of print' at this 
stage. Early View articles are complete and final. They have been fully reviewed, revised and 
edited for publication, and the authors' final corrections have been incorporated. Because they 
are in final form, no changes can be made after online publication. The nature of Early View 
articles means that they do not yet have volume, issue or page numbers, so Early View 
articles cannot be cited in the traditional way. They are therefore given a Digital Object 
Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an 
issue. After the issue publication, the DOI remains valid and can continue to be used to cite 
and access the article. To receive an e-mail alert once your paper has been published, please 
register via Author Services. 
 
Proofs 
 
The corresponding author will receive an email alert containing a link to a web site. A 
working e-mail address must therefore be provided for the corresponding author. The proof 
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can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader 
will be required in order to read this file. This software can be downloaded (free of charge) 
from the website. This will enable the file to be opened, read on screen and printed out in 
order for any corrections to be added. Further instructions will be sent with the proof. Hard 
copy proofs will be posted if no e-mail address is available. Excessive changes made by the 
author in the proofs, excluding typesetting errors, will be charged separately. 
 
Offprints 
 
Free access to the final PDF offprint of your article will be available via Author Services 
only. Please therefore sign up for Author Services if you would like to access your article 
PDF offprint and enjoy the many other benefits the service offers. Additional paper offprints 
may be ordered online. Please click on the following link for more details: 
http://offprint.cosprinters.com/blackwell. If you have queries about offprints please email 
offprint@cosprinters.com. 
 
 
